inclusion criteria: healthy adult volunteers, aged 21 to 50 years old, men or women. subjects negative for human immunodeficiency virus (hiv antibody screen), hepatitis b virus surface antigen (hbsag) and hepatitis c virus (hcv antibody screen). subjects who are willing to comply with the requirements of the study protocol, attend scheduled visits and make themselves available for the duration of the study with access to a consistent means of telephone contact. subjects who give written informed consent approved by the internal review board governing the site. satisfactory baseline medical assessment as assessed by physical examination and a stable health status. normal laboratory values must be within normal range of the assessing site or show minor variations that are deemed not clinically significant as judged by the investigator and acceptable for study entry. accessible vein in the forearm for blood collection. female subjects of childbearing potential may be enrolled in the study if they have negative urine pregnancy tests on the day of screening and day of admission. female subjects of non-childbearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. both male (if he has a partner of childbearing potential) and female subjects (of childbearing potential) must agree to use adequate and reliable contraceptive measures (e.g. spermicides, condoms, contraceptive pills, etc.) or practice abstinence throughout the duration of the study (up to 30 days post-dosing).

inclusion criteria: healthy adult volunteers, aged 21 to 50 years old, men or women. subjects negative for human immunodeficiency virus (hiv antibody screen), hepatitis b virus surface antigen (hbsag) and hepatitis c virus (hcv antibody screen). subjects who are willing to comply with the requirements of the study protocol, attend scheduled visits and make themselves available for the duration of the study with access to a consistent means of telephone contact. subjects who give written informed consent approved by the internal review board governing the site. satisfactory baseline medical assessment as assessed by physical examination and a stable health status. normal laboratory values must be within normal range of the assessing site or show minor variations that are deemed not clinically significant as judged by the investigator and acceptable for study entry. accessible vein in the forearm for blood collection. female subjects of childbearing potential may be enrolled in the study if they have negative urine pregnancy tests on the day of screening and day of admission. female subjects of non-childbearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. both male (if he has a partner of childbearing potential) and female subjects (of childbearing potential) must agree to use adequate and reliable contraceptive measures (e.g. spermicides, condoms, contraceptive pills, etc.) or practice abstinence throughout the duration of the study (up to 30 days post-dosing).

inclusion criteria: 1. healthy adult volunteers, aged 21 to 50 years old, men or women. 2. subjects negative for human immunodeficiency virus (hiv antibody screen), hepatitis b virus surface antigen (hbsag) and hepatitis c virus (hcv antibody screen). 3. subjects who are willing to comply with the requirements of the study protocol, attend scheduled visits and make themselves available for the duration of the study with access to a consistent means of telephone contact. 4. subjects who give written informed consent approved by the internal review board governing the site. 5. satisfactory baseline medical assessment as assessed by physical examination and a stable health status. normal laboratory values must be within normal range of the assessing site or show minor variations that are deemed not clinically significant as judged by the investigator and acceptable for study entry. 6. accessible vein in the forearm for blood collection. 7. female subjects of childbearing potential may be enrolled in the study if they have negative urine pregnancy tests on the day of screening and day of admission. 8. female subjects of non-childbearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. 9. both male (if he has a partner of childbearing potential) and female subjects (of childbearing potential) must agree to use adequate and reliable contraceptive measures (e.g. spermicides, condoms, contraceptive pills, etc.) or practice abstinence throughout the duration of the study (up to 30 days post-dosing).

inclusion criteria: 1. healthy adult volunteers, aged 21 to 50 years old, men or women. 2. subjects negative for human immunodeficiency virus (hiv antibody screen), hepatitis b virus surface antigen (hbsag) and hepatitis c virus (hcv antibody screen). 3. subjects who are willing to comply with the requirements of the study protocol, attend scheduled visits and make themselves available for the duration of the study with access to a consistent means of telephone contact. 4. subjects who give written informed consent approved by the internal review board governing the site. 5. satisfactory baseline medical assessment as assessed by physical examination and a stable health status. normal laboratory values must be within normal range of the assessing site or show minor variations that are deemed not clinically significant as judged by the investigator and acceptable for study entry. 6. accessible vein in the forearm for blood collection. 7. female subjects of childbearing potential may be enrolled in the study if they have negative urine pregnancy tests on the day of screening and day of admission. 8. female subjects of non-childbearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. 9. both male (if he has a partner of childbearing potential) and female subjects (of childbearing potential) must agree to use adequate and reliable contraceptive measures (e.g. spermicides, condoms, contraceptive pills, etc.) or practice abstinence throughout the duration of the study (up to 30 days post-dosing).